BioMarin Pharmaceutical Inc. (BVMF:B1MR34)

Market Cap	55.33B
Revenue (ttm)	16.49B
Net Income (ttm)	2.77B
Shares Out	n/a
EPS (ttm)	14.29
PE Ratio	19.95
Forward PE	11.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	277
Average Volume	243
Open	146.75
Previous Close	146.42
Day's Range	145.04 - 146.75
52-Week Range	139.16 - 208.72
Beta	0.30
RSI	45.22
Earnings Date	Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1MR34

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD